INTRODUCTION
45 Osteoarthritis (OA) is an important pathology of veterinary and human patients. It is documented 46 as the first cause of chronic joint pain in human patients in the USA, causing tremendous 47 decreases in productivity and economic losses (Pomonis et al., 2005) . Currently available 48 treatments are centered on symptom relief and, although knowledge of the disease process has 49 significantly evolved over the past decades, the pathology and symptomatology remain only 50 partially understood (Fernihough et al., 2004; Pelletier, Martel-Pelletier & Abramson, 2001 ). It 51 is believed that peripheral and centralized sensitization play a role in the creation and 52 maintenance of a chronic painful state and that it is imperfectly correlated to radiographic or 53 histologic evaluation of the affected joints (Fernihough et al., 2004; Hawker, 2012; Im et al., 54 2010; Zhang, Ren & Dubner, 2013) .
55
56 Different animal models have been employed for the investigation of pain mechanisms and 57 evaluation of potential treatments. The ideal animal model should be reproducible, reliable and 58 offer the best translational value possible (Bendele, 2001 ; Little & Smith, 2008) . Classically, the 59 intra-articular injection of monosodium iodoacetate (MIA) in rats has been used for the 60 evaluation of analgesic OA therapies. It relies on the disruption of chondrocyte glycolysis, 61 causing an interruption in their metabolism and subsequent cartilage damage (Guzman et al., 62 2003 ; Kobayashi et al., 2003; Pomonis et al., 2005) . It is believed to cause structural changes 63 that mimic the human pathology and, although pathogenesis is different from the natural disease, 64 weight bearing changes (Pomonis et al. 2005 ) and centralized pain were documented (Ferland et 65 al., 2011; Fernihough et al. 2004; Im et al., 2010; Zhang, Ren & Dubner, 2013) . Unfortunately, 66 the MIA model causes temporary changes of short duration and relies on a disease mechanism 67 different from human OA, which could limit the predictability of therapeutic effect of analgesics 68 and disease modifying agents. Different surgical rat models have also been used with various 69 results and outcome measures. Until now, none of the surgical model has satisfied all the desired 70 criteria (Barve et al., 2007; Bendele, 2001; Little & Zaki, 2012) .
72
In the search for better animal models, this pilot study was performed with the goal of evaluating 73 pain functional outcomes and spinal biomarkers between three surgical rat models of OA pain, 74 i.e. destabilization of the medial meniscus (DMM), cranial cruciate ligament transection (CCLT) 75 and the combination of both (Combo), and comparing those results to the MIA model. The use of 76 DMM was previously studied in mice for structural and biomarker assessment (Das et al., 2010; 77 Inglis et al., 2008) . To our knowledge, it is the first application of this surgical model in rats. It 78 was selected because of the ease of induction and standardization compared to the 79 meniscectomy. Consequently, the Combo model appears as a new surgical OA model in rats.
80
The research hypothesis was that surgical OA induction would be accompanied by quantifiable 81 neurophysiological modifications compatible with the presence of chronic non-physiologic pain. . In the present study, SP, CGRP, bradykinin (BK) and somatostatin 168 (SST) were analyzed by high performance liquid chromatography-mass spectrometry and 169 expressed in fmol/mg of spinal cord homogenates (1:5 w/v in 0.25% TFA solution) according to 170 a previously described technique .
172 Statistical analysis
173 The %BW and PWT data were expressed as the average of the three trials of each paw. The 174 symmetry index was used only to statistically confirm the impressions given by the graphs, when 175 necessary.
176 The normality of the data (Shapiro-Wilk test) and the homogeneity of variance were confirmed 177 using the absolute values of the residuals of the mixed model, when appropriate. Unless 178 indicated otherwise, hypothesis were two-sided and alpha-value was set at 0.05. 179 For each model, the first tested hypothesis was that there was at least one evaluation day when 180 the outcome was different from the baseline. A linear mixed model for repeated measures was 181 used. Multiple comparisons were performed using the Dunnett procedure. Then, the surgical 182 models that presented a significant change over time were compared. The second hypothesis was 183 that at least one model differed. The alpha-value was set at 0.1 at that time to maximize the 184 chances of significant results in a comparative pilot study setting. It is acceptable to set a higher 185 alpha value, when the goal of the study is to find an effect that could lead to a promising 186 scientific discovery. This allows to increase the power and consequently decrease the risk of 187 Type II error, but it also increases the chances of making a Type I error (i.e., saying there is a 258 have shown alterations resulting from biomechanical instability if the rats had been more mobile 259 and active, which was not part of the current study design (Appleton et al., 2007) . Hence, they 260 could remain interesting models in specific study settings. However, the changes induced by 261 both the MIA intra-articular injection and Combo surgery led to biomechanical (SWB), sensory 262 (PTW) and nociceptive neuropeptides changes in the same research context.
263
The significant weight shift to the left hind paw on SWB in the MIA group could be interpreted 264 as an early occurring but non-persistent biomechanical change since the %BW values for the 265 MIA group were not different from baseline after D7. This phenomenon was not observed in the 266 surgical groups and could constitute a major difference between the MIA and surgical models.
267 This contralateral weight shift could be indicative of major discomfort in the (affected) right hind 268 limb with the rat seeking to relieve itself from this acute insult, whereas the more progressive 5 Notes: For each group, the best structure of the covariance model was assessed using a graphical 6 method (plots of covariance vs. lag in time between pairs of observation compared to different 7 covariance model), and using information criteria that measure the relative fit of competing 8 covariance model: normal distribution, compound symmetry covariance structure (Sham, DMM 9 and MIA groups); heterogeneous compound symmetry covariance structure (CCLT group), and 10 type-1 auto regressive covariance structure (Combo group). For the baseline to specific day 11 comparison, adjusted P-value for multiple comparisons was obtained using the Dunnett 12 procedure. A bold font highlights a significant difference. 5 Notes: For each group, the best structure of the covariance model was assessed using a graphical 6 method (plots of covariance vs. lag in time between pairs of observation compared to different 7 covariance model), and using information criteria that measure the relative fit of competing 8 covariance model: normal distribution, compound symmetry covariance structure (Sham, CCLT, 9 DMM, Combo and MIA groups). For the baseline to specific day comparison, adjusted P-value 10 for multiple comparisons was obtained using the Dunnett procedure. A bold font highlights a 11 significant difference. Time is distributed differently for the surgical (D-1, D14, D28 and D42) and the MIA (D-1, D3, D7, D14, D21) groups. A star indicates a day when there is a statistically significant decreased value compared to its baseline (see Table 1 for details). Time is distributed differently for the surgical (D-1, D14, D28 and D42) and the MIA (D-1, D3, D7, D14, D21) groups. A star indicates a day when there is a statistically significant decreased value compared to its baseline (see Table 2 for details).
